Immunopathology Section, Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD 20895, USA.
Ocul Immunol Inflamm. 2009 Nov-Dec;17(6):375-9. doi: 10.3109/09273940903434804.
Basic science and clinical investigations in cancer research have contributed to our understanding of the genetic causes of various neoplasms and discovery of novel therapeutic interventions to fight malignancies such as lymphoma. During this exciting time, we have witnessed the advent of new technologies to further characterize primary intraocular lymphoma (PIOL), or retinal lymphoma, which is selected as the first "Disease of the Year" by Ocular Immunology and Inflammation. Different comprehensive aspects of PIOL, including epidemiology, clinical manifestations, diagnosis, pathophysiology, therapy, and animal models are discussed. The future of PIOL holds an opportunity to really understand the unique cytologic, histopathologic, physiological and immunologic features, as well as the genotypic traits (gene expression, interaction, polymorphism, epigenetics, etc.) and epidemiology. This information will empower us to truly make a difference in patients' managements with this devastating disease. While most of this technology already exists, much work still needs to be done to make translational therapy a reality for PIOL patients in the future.
癌症研究中的基础科学和临床研究有助于我们了解各种肿瘤的遗传原因，并发现治疗淋巴瘤等恶性肿瘤的新治疗方法。在这个令人兴奋的时期，我们见证了新技术的出现，这些技术进一步描述了原发性眼内淋巴瘤（PIOL）或视网膜淋巴瘤，它被眼部免疫学和炎症选为首个“年度疾病”。PIOL 的不同综合方面，包括流行病学、临床表现、诊断、病理生理学、治疗和动物模型，都进行了讨论。PIOL 的未来有机会真正了解其独特的细胞学、组织病理学、生理学和免疫学特征，以及基因型特征（基因表达、相互作用、多态性、表观遗传学等）和流行病学。这些信息将使我们能够真正在患者管理方面有所作为，治疗这种毁灭性疾病。虽然这些技术大多已经存在，但为了使 PIOL 患者的转化治疗在未来成为现实，仍有许多工作需要完成。
